Epizyme, Inc. (EPZM) Financial Statements (2024 and earlier)
Company Profile
Business Address |
400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
6/30/2022 MRQ | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments, including: | 176,800 | 373,600 | 381,100 | 240,300 | 276,400 | 242,200 | |||
Cash and cash equivalents | 98,336 | 168,215 | 139,482 | 86,671 | 226,664 | 77,895 | |||
Short-term investments | 78,454 | 205,391 | 241,605 | 153,633 | 49,775 | 164,297 | |||
Other undisclosed cash, cash equivalents, and short-term investments | 10 | (6) | 13 | (4) | (39) | 8 | |||
Receivables | 6,572 | 3,105 | 2,567 | 20,067 | 382 | 23 | |||
Other undisclosed current assets | 22,671 | 28,388 | 15,510 | 12,168 | 9,022 | 6,449 | |||
Total current assets: | 206,043 | 405,093 | 399,177 | 272,535 | 285,804 | 248,672 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 20,054 | 17,305 | 21,206 | ✕ | ✕ | ✕ | |||
Property, plant and equipment | 1,545 | 2,152 | 2,219 | 2,057 | 2,527 | 3,124 | |||
Intangible assets, net (including goodwill) | 42,849 | 47,002 | |||||||
Intangible assets, net (excluding goodwill) | 42,849 | 47,002 | |||||||
Other noncurrent assets | 18,509 | 2,021 | 1,987 | 909 | 1,028 | 645 | |||
Total noncurrent assets: | 82,957 | 68,480 | 25,412 | 2,966 | 3,555 | 3,769 | |||
TOTAL ASSETS: | 289,000 | 473,573 | 424,589 | 275,501 | 289,359 | 252,441 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 41,042 | 38,735 | 31,331 | 24,480 | 24,550 | 21,001 | |||
Accounts payable | 10,265 | 10,163 | 8,782 | 4,780 | 7,001 | 4,994 | |||
Accrued liabilities | 30,777 | 28,572 | 22,549 | 19,700 | 17,549 | 16,007 | |||
Debt | 3,039 | 16 | 110 | 620 | |||||
Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | 13,300 | ✕ | ✕ | ||
Other liabilities | 16 | 37 | 4 | ||||||
Other undisclosed current liabilities | 4,154 | 4,665 | |||||||
Total current liabilities: | 45,196 | 43,400 | 34,386 | 37,833 | 24,664 | 21,621 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 18,497 | 15,409 | 19,120 | 53 | 110 | ||||
Capital lease obligations | ✕ | ✕ | ✕ | ✕ | 53 | 110 | |||
Liabilities, other than long-term debt | 11,950 | 21 | 3,844 | 4,606 | 29,324 | 29,010 | |||
Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | 28,809 | 28,809 | ||
Deferred revenue | 11,950 | 3,806 | ✕ | ✕ | ✕ | ||||
Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | 3,806 | ✕ | ✕ | ||
Other liabilities | 21 | 38 | 800 | 515 | 201 | ||||
Operating lease, liability | 18,497 | 15,409 | 19,120 | ✕ | ✕ | ✕ | |||
Total noncurrent liabilities: | 30,447 | 15,430 | 22,964 | 4,659 | 29,324 | 29,120 | |||
Total liabilities: | 75,643 | 58,830 | 57,350 | 42,492 | 53,988 | 50,741 | |||
Equity | |||||||||
Equity, attributable to parent | (20,688) | 184,897 | 331,137 | 233,009 | 235,371 | 201,700 | |||
Preferred stock | 36,127 | 36,127 | 37,432 | ||||||
Common stock | 11 | 10 | 10 | 8 | 7 | 6 | |||
Additional paid in capital | 1,183,006 | 1,137,470 | 1,050,695 | 819,779 | 723,510 | 555,473 | |||
Accumulated other comprehensive income (loss) | 3 | 3 | 19 | (54) | (49) | (106) | |||
Accumulated deficit | (1,239,835) | (988,713) | (757,019) | (586,724) | (488,097) | (353,673) | |||
Total equity: | (20,688) | 184,897 | 331,137 | 233,009 | 235,371 | 201,700 | |||
Other undisclosed liabilities and equity | 234,045 | 229,846 | 36,102 | ||||||
TOTAL LIABILITIES AND EQUITY: | 289,000 | 473,573 | 424,589 | 275,501 | 289,359 | 252,441 |
Income Statement (P&L) ($ in thousands)
6/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 37,427 | 15,762 | 23,800 | 21,700 | 10,000 | 8,007 | ||
Revenue, net | ✕ | ✕ | ✕ | ✕ | ✕ | 10,000 | 8,007 | |
Cost of revenue | (10,498) | (5,067) | ||||||
Gross profit: | 26,929 | 10,695 | 23,800 | 21,700 | 10,000 | 8,007 | ||
Operating expenses | (264,921) | (236,111) | (200,942) | (149,805) | (146,842) | (119,833) | ||
Operating loss: | (237,992) | (225,416) | (177,142) | (128,105) | (136,842) | (111,826) | ||
Nonoperating income (expense) | (13,108) | (6,164) | 6,905 | 4,532 | 2,197 | 1,614 | ||
Loss from continuing operations before income taxes: | (251,100) | (231,580) | (170,237) | (123,573) | (134,645) | (110,212) | ||
Income tax expense (benefit) | (22) | (114) | (58) | (57) | 336 | |||
Loss from continuing operations: | (251,122) | (231,694) | (170,295) | (123,630) | (134,309) | (110,212) | ||
Loss before gain (loss) on sale of properties: | ✕ | (251,122) | (231,694) | (170,295) | (123,630) | (134,309) | (110,212) | |
Net loss attributable to parent: | (251,122) | (231,694) | (170,295) | (123,630) | (134,309) | (110,212) | ||
Other undisclosed net loss available to common stockholders, basic | (2,940) | |||||||
Net loss available to common stockholders, diluted: | (251,122) | (231,694) | (173,235) | (123,630) | (134,309) | (110,212) |
Comprehensive Income ($ in thousands)
6/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (251,122) | (231,694) | (170,295) | (123,630) | (134,309) | (110,212) | ||
Comprehensive loss: | (251,122) | (231,694) | (170,295) | (123,630) | (134,309) | (110,212) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (16) | 73 | (5) | 57 | (106) | |||
Comprehensive loss, net of tax, attributable to parent: | (251,122) | (231,710) | (170,222) | (123,635) | (134,252) | (110,318) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.